Susanne Elisabeth Hosbond1, Axel Cosmus Pyndt Diederichsen2, Lotte Saaby3, Lars Melholt Rasmussen4, Jess Lambrechtsen5, Henrik Munkholm6, Niels Peter Rønnow Sand7, Oke Gerke8, Tina Svenstrup Poulsen9, Hans Mickley3. 1. Department of Cardiology, Odense University Hospital, Odense, Denmark; OPEN Odense Patient Data Explorative Network, Odense University Hospital, Odense, Denmark. Electronic address: susanne.hosbond@rsyd.dk. 2. Department of Cardiology, Odense University Hospital, Odense, Denmark; Centre for Individualized Medicine of Arterial Diseases, Odense University Hospital, Denmark; OPEN Odense Patient Data Explorative Network, Odense University Hospital, Odense, Denmark. 3. Department of Cardiology, Odense University Hospital, Odense, Denmark; OPEN Odense Patient Data Explorative Network, Odense University Hospital, Odense, Denmark. 4. Department of Biochemistry and Pharmacology, Odense University Hospital, Denmark; Centre for Individualized Medicine of Arterial Diseases, Odense University Hospital, Denmark. 5. Department of Cardiology, Odense University Hospital, Svendborg, Denmark. 6. Department of Cardiology, Lillebaelt Hospital, Vejle Hospital, Denmark. 7. Department of Cardiology, Hospital of South West Denmark, Esbjerg, Denmark; Institute of Regional Health Services Research, University of Southern Denmark, Denmark. 8. Department of Nuclear Medicine, Odense University Hospital, Denmark; Centre of Health Economics Research, University of Southern Denmark, Denmark. 9. Department of Cardiology, Odense University Hospital, Odense, Denmark.
Abstract
PURPOSE: The biomarker Osteoprotegerin (OPG) is associated with coronary artery disease (CAD). The main purpose of this study was to evaluate the diagnostic value of OPG in healthy subjects and in patients with suspected angina pectoris (AP). METHODS: A total of 1805 persons were enrolled: 1152 healthy subjects and 493 patients with suspected AP. For comparison 160 patients with acute myocardial infarction (MI) were included. To uncover subclinical coronary atherosclerosis, a non-contrast cardiac-CT scan was performed in healthy subjects; while in patients with suspected AP a contrast coronary angiography was used to detect significant stenosis. OPG concentrations were analyzed and compared between groups. ROC-analyses were performed to estimate OPG cut-off values. RESULTS: OPG concentrations increased according to disease severity with the highest levels found in patients with acute MI. No significant difference (p = 0.97) in OPG concentrations was observed between subgroups of healthy subjects according to severity of coronary calcifications. A significant difference (p < 0.0001) in OPG concentrations was found between subgroups of patients with suspected stable AP according to severity of CAD. ROC-analysis showed an AUC of 0.62 (95% CI: 0.57-0.67). The optimal cut-off value of OPG (<2.29 ng/mL) had a sensitivity of 56.2% (95% CI: 49.2-63.0%) and a specificity of 62.9% (95% CI: 57.3-68.2%). CONCLUSION: OPG cannot be used to differentiate between healthy subjects with low versus high levels of coronary calcifications. In patients with suspected AP a single OPG measurement is of limited use in the diagnosis of CAD.
PURPOSE: The biomarker Osteoprotegerin (OPG) is associated with coronary artery disease (CAD). The main purpose of this study was to evaluate the diagnostic value of OPG in healthy subjects and in patients with suspected angina pectoris (AP). METHODS: A total of 1805 persons were enrolled: 1152 healthy subjects and 493 patients with suspected AP. For comparison 160 patients with acute myocardial infarction (MI) were included. To uncover subclinical coronary atherosclerosis, a non-contrast cardiac-CT scan was performed in healthy subjects; while in patients with suspected AP a contrast coronary angiography was used to detect significant stenosis. OPG concentrations were analyzed and compared between groups. ROC-analyses were performed to estimate OPG cut-off values. RESULTS:OPG concentrations increased according to disease severity with the highest levels found in patients with acute MI. No significant difference (p = 0.97) in OPG concentrations was observed between subgroups of healthy subjects according to severity of coronary calcifications. A significant difference (p < 0.0001) in OPG concentrations was found between subgroups of patients with suspected stable AP according to severity of CAD. ROC-analysis showed an AUC of 0.62 (95% CI: 0.57-0.67). The optimal cut-off value of OPG (<2.29 ng/mL) had a sensitivity of 56.2% (95% CI: 49.2-63.0%) and a specificity of 62.9% (95% CI: 57.3-68.2%). CONCLUSION:OPG cannot be used to differentiate between healthy subjects with low versus high levels of coronary calcifications. In patients with suspected AP a single OPG measurement is of limited use in the diagnosis of CAD.
Authors: Nienke M S Golüke; Marit A Schoffelmeer; Annemarieke De Jonghe; Mariëlle H Emmelot-Vonk; Pim A De Jong; Huiberdina L Koek Journal: Bone Rep Date: 2022-06-18
Authors: Mirthe Dekker; Farahnaz Waissi; Max J M Silvis; Joelle V Bennekom; Arjan H Schoneveld; Robbert J de Winter; Ivana Isgum; Nikolas Lessmann; Birgitta K Velthuis; Gerard Pasterkamp; Arend Mosterd; Leo Timmers; Dominique P V de Kleijn Journal: Sci Rep Date: 2021-09-23 Impact factor: 4.379
Authors: Philip D Adamson; Amanda Hunter; Debbie M Madsen; Anoop S V Shah; David A McAllister; Tania A Pawade; Michelle C Williams; Colin Berry; Nicholas A Boon; Marcus Flather; John Forbes; Scott McLean; Giles Roditi; Adam D Timmis; Edwin J R van Beek; Marc R Dweck; Hans Mickley; Nicholas L Mills; David E Newby Journal: Circ Cardiovasc Qual Outcomes Date: 2018-02